Details
Stereochemistry | ABSOLUTE |
Molecular Formula | C6H14O6 |
Molecular Weight | 182.1718 |
Optical Activity | UNSPECIFIED |
Defined Stereocenters | 4 / 4 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO
InChI
InChIKey=FBPFZTCFMRRESA-JGWLITMVSA-N
InChI=1S/C6H14O6/c7-1-3(9)5(11)6(12)4(10)2-8/h3-12H,1-2H2/t3-,4+,5-,6-/m1/s1
DescriptionSources: https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=16cc9d47-5382-4237-ab84-f22c5436fe2ehttps://www.drugbank.ca/drugs/DB00742 | https://www.accessdata.fda.gov/drugsatfda_docs/nda/2010/022368Orig1s000LBL.pdf | https://www.accessdata.fda.gov/drugsatfda_docs/label/2005/013684s091lbl.pdfCurator's Comment: description was created based on several sources, including:
http://www.sailhome.org/Concerns/Vaccines.html
Sources: https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=16cc9d47-5382-4237-ab84-f22c5436fe2ehttps://www.drugbank.ca/drugs/DB00742 | https://www.accessdata.fda.gov/drugsatfda_docs/nda/2010/022368Orig1s000LBL.pdf | https://www.accessdata.fda.gov/drugsatfda_docs/label/2005/013684s091lbl.pdf
Curator's Comment: description was created based on several sources, including:
http://www.sailhome.org/Concerns/Vaccines.html
Mannitol is an osmotic diuretic that is metabolically inert in humans and occurs naturally, as a sugar or sugar alcohol, in fruits and vegetables. Mannitol elevates blood plasma osmolality, resulting in enhanced flow of water from tissues, including the brain and cerebrospinal fluid, into interstitial fluid and plasma. As a result, cerebral edema, elevated intracranial pressure, and cerebrospinal fluid volume and pressure may be reduced. Mannitol (marketed under the brand Osmitrol) may also be used for the promotion of diuresis before irreversible renal failure becomes established; the promotion of urinary excretion of toxic substances; as an Antiglaucoma agent; and as a renal function diagnostic aid. Mannitol, the active ingredient in ARIDOL, is indicated for the assessment of bronchial hyperresponsiveness in patients 6 years of age or older who do not have clinically apparent asthma. Mannitol is an osmotic diuretic that is metabolically inert in humans and occurs naturally, as a sugar or sugar alcohol, in fruits and vegetables. Mannitol elevates blood plasma osmolality, resulting in enhanced flow of water from tissues, including the brain and cerebrospinal fluid, into interstitial fluid and plasma. As a result, cerebral edema, elevated intracranial pressure, and cerebrospinal fluid volume and pressure may be reduced. As a diurectic mannitol induces diuresis because it is not reabsorbed in the renal tubule, thereby increasing the osmolality of the glomerular filtrate, facilitating excretion of water, and inhibiting the renal tubular reabsorption of sodium, chloride, and other solutes. Mannitol promotes the urinary excretion of toxic materials and protects against nephrotoxicity by preventing the concentration of toxic substances in the tubular fluid. As an Antiglaucoma agent mannitol elevates blood plasma osmolarity, resulting in enhanced flow of water from the eye into plasma and a consequent reduction in intraocular pressure. As a renal function diagnostic aid mannitol is freely filtered by the glomeruli with less than 10% tubular reabsorption. Therefore, its urinary excretion rate may serve as a measurement of glomerular filtration rate (GFR).
CNS Activity
Sources: https://www.ncbi.nlm.nih.gov/pubmed/?term=26035307https://www.anaesthesiamcq.com/FluidBook/fl8_5.php
Curator's Comment: Mannitol does not cross the blood-brain barrier so an elevated plasma osmolality due to an infusion of hypertonic mannitol is effective in removing fluid from the brain.
Originator
Sources: Alternative Sweeteners, Third Edition, Revised and Expanded. Ed. Lyn O'Brien-Nabors. CRC Press, 2001 . - pp. 572https://books.google.ru/books?id=_F1YSezlIzwC&pg=PA268&lpg=PA268&dq=mannitol retrieved from Carbohydrates, p.268
Curator's Comment: The first sugar alcohol isolated was mannitol from manna of ash (Fraxinus sp.) by Proust in 1806
Approval Year
Conditions
Condition | Modality | Targets | Highest Phase | Product |
---|---|---|---|---|
Preventing | Osmitrol Approved UseOsmitrol Injection (Mannitol Injection, USP) is indicated for:
The promotion of diuresis, in the prevention and/or treatment of the oliguric phase of acute renal
failure before irreversible renal failure becomes established;
The reduction of intracranial pressure and treatment of cerebral edema by reducing brain mass;
The reduction of elevated intraocular pressure when the pressure cannot be lowered by other means,
and promoting the urinary excretion of toxic substances. Launch Date1964 |
|||
Primary | Osmitrol Approved UseOsmitrol Injection (Mannitol Injection, USP) is indicated for:
The promotion of diuresis, in the prevention and/or treatment of the oliguric phase of acute renal
failure before irreversible renal failure becomes established;
The reduction of intracranial pressure and treatment of cerebral edema by reducing brain mass;
The reduction of elevated intraocular pressure when the pressure cannot be lowered by other means,
and promoting the urinary excretion of toxic substances. Launch Date1964 |
|||
Primary | Osmitrol Approved UseOsmitrol Injection (Mannitol Injection, USP) is indicated for:
The promotion of diuresis, in the prevention and/or treatment of the oliguric phase of acute renal
failure before irreversible renal failure becomes established;
The reduction of intracranial pressure and treatment of cerebral edema by reducing brain mass;
The reduction of elevated intraocular pressure when the pressure cannot be lowered by other means,
and promoting the urinary excretion of toxic substances. Launch Date1964 |
|||
Diagnostic | ARIDOL Approved UseMannitol, the active ingredient in ARIDOL, is indicated for the assessment of bronchial hyperresponsiveness in patients 6 years of age or older who do not have clinically apparent asthma. Launch Date2010 |
|||
Palliative | Bronchitol Approved UseBronchitol is indicated for the treatment of cystic fibrosis (CF) in adults aged 18 years and above as
an add-on therapy to best standard of care. Launch Date2012 |
|||
Primary | SORBITOL 3.3% IN PLASTIC CONTAINER Approved UseRenagel Capsules are indicated for the reduction of serum phosphorus in patients with end-stage renal disease (ESRD). The safety and efficacy of Renagel Capsules in ESRD patients who are not on hemodialysis have not been studied. In hemodialysis patients, Renagel decreases the incidence of
hypercalcemic episodes relative to patients on calcium acetate treatment. Launch Date1978 |
|||
Primary | Unknown Approved UseUnknown |
PubMed
Title | Date | PubMed |
---|---|---|
Quinone reductase inhibitors block SAPK/JNK and NFkappaB pathways and potentiate apoptosis. | 1999 Oct 29 |
|
Sorbitol as a marker for drug-induced decreases of variable duration in liver blood flow in healthy volunteers. | 2000 Dec |
|
Osmotherapy for elevated intracranial pressure: a critical reappraisal. | 2000 Jan |
|
Intestinal permeability tests in coeliac disease. | 2001 |
|
Hypertonicity stimulates Cl(-) transport in the intestine of fresh water acclimated eel, Anguilla anguilla. | 2001 |
|
The effect of Celsior solution on 12-hour cardiac preservation in comparison with University of Wisconsin solution. | 2001 Apr |
|
Effect of high glucose concentration on the synthesis of monocyte chemoattractant protein-1 in human peritoneal mesothelial cells: involvement of protein kinase C. | 2001 Apr |
|
Transcytosis of retinol-binding protein across renal proximal tubule cells after megalin (gp 330)-mediated endocytosis. | 2001 Apr |
|
Methemoglobin oxidation of N-acetylbenzidine to form a sulfinamide. | 2001 Apr |
|
Roles of glucitol in the GutR-mediated transcription activation process in Bacillus subtilis: glucitol induces GutR to change its conformation and to bind ATP. | 2001 Aug 10 |
|
Comparison of culture, PCR and immunoassays for detecting Escherichia coli O157 following enrichment culture and immunomagnetic separation performed on naturally contaminated raw meat products. | 2001 Aug 15 |
|
Effect of osmolytes and chaperone-like action of P-protein on folding of nucleocapsid protein of Chandipura virus. | 2001 Aug 17 |
|
Permeability of the proximal and distal rat colon crypt and surface epithelium to hydrophilic molecules. | 2001 Feb |
|
Preferential induction of a 9-lipoxygenase by salt in salt-tolerant cells of Citrus sinensis L. Osbeck. | 2001 Feb |
|
[Intraoperative complications of 697 consecutive operative hysteroscopies]. | 2001 Feb |
|
Intestinal permeability in adult patients with growth hormone deficiency. | 2001 Feb |
|
Improving water stress tolerance of the biocontrol yeast Candida sake grown in molasses-based media by physiological manipulation. | 2001 Feb |
|
The transmembrane protein occludin of epithelial tight junctions is a functional target for serine peptidases from faecal pellets of Dermatophagoides pteronyssinus. | 2001 Feb |
|
Membrane-bound sugar alcohol dehydrogenase in acetic acid bacteria catalyzes L-ribulose formation and NAD-dependent ribitol dehydrogenase is independent of the oxidative fermentation. | 2001 Jan |
|
Detection and characterization of verotoxin-producing strains among sorbitol non-fermenting Escherichia coli. | 2001 Jul-Sep |
|
Recombinant Microdochium nivale carbohydrate oxidase and its application in an amperometric glucose sensor. | 2001 Jun |
|
Melatonin counteracts potentiation by lysophosphatidylcholine of serotonin-induced vasoconstriction in human umbilical artery: relation to calcium influx. | 2001 Mar |
|
Identification of a mannitol transporter, AgMaT1, in celery phloem. | 2001 Mar |
|
Isolation and phenotypic characterization of Pseudomonas aeruginosa pseudorevertants containing suppressors of the catabolite repression control-defective crc-10 allele. | 2001 Mar 15 |
|
Singlet oxygen generation from phosphatidylcholine hydroperoxide in the presence of copper. | 2001 Mar 2 |
|
Crystal structures of the maltodextrin/maltose-binding protein complexed with reduced oligosaccharides: flexibility of tertiary structure and ligand binding. | 2001 Mar 9 |
|
Effects of P-glycoprotein on cell volume regulation in mouse proximal tubule. | 2001 May |
|
Alveolar epithelial barrier functions in ventilated perfused rabbit lungs. | 2001 May |
|
Theoretical description of transdermal transport of hydrophilic permeants: application to low-frequency sonophoresis. | 2001 May |
|
Design and validation of an annular shear cell for pharmaceutical powder testing. | 2001 May |
|
The production of reactive oxygen species by irradiated camphorquinone-related photosensitizers and their effect on cytotoxicity. | 2001 May |
|
Determination of D-sorbitol in human erythrocytes by an enzymatic fluorometric method with an improved deproteinization procedure. | 2001 Nov |
|
p38 MAP kinase mediates stress-induced leukotriene synthesis in a human B-lymphocyte cell line. | 2001 Nov |
|
Cloning and expression of a fungal L-arabinitol 4-dehydrogenase gene. | 2001 Nov 2 |
|
Synthesis of 3-hexuloses from 1,2:5,6-di-O-isopropylidenehexitols. | 2001 Sep 28 |
|
Regulation of carbon utilization by sulfur availability in Escherichia coli and Salmonella typhimurium. | 2002 Jan |
|
Application of NAD-dependent polyol dehydrogenases for enzymatic mannitol/sorbitol production with coenzyme regeneration. | 2003 |
|
Role of the different mitogen-activated protein kinase subfamilies in the stimulation of dog and human thyroid epithelial cell proliferation by cyclic adenosine 5'-monophosphate and growth factors. | 2003 Apr |
|
Crystal structure of Pseudomonas fluorescens mannitol 2-dehydrogenase: evidence for a very divergent long-chain dehydrogenase family. | 2003 Feb 1 |
|
Characterization of recombinant xylitol dehydrogenase from Galactocandida mastotermitis expressed in Escherichia coli. | 2003 Feb 1 |
|
Genetic relationships among avian isolates classified as Pasteurella haemolytica, 'Actinobacillus salpingitidis' or Pasteurella anatis with proposal of Gallibacterium anatis gen. nov., comb. nov. and description of additional genomospecies within Gallibacterium gen. nov. | 2003 Jan |
|
Effect of glucose on assimilatory sulphate reduction in Arabidopsis thaliana roots. | 2003 Jul |
|
[Comparative analysis of dependence of saliva sorbitol and fructosamine levels on blood glucose level in patients with diabetes]. | 2004 |
|
Growth and characterisation of primary bovine colon epithelial cells in vitro. | 2004 Dec |
|
Exploration of essential gene functions via titratable promoter alleles. | 2004 Jul 9 |
|
Anaphylaxis to excipient mannitol: evidence for an immunoglobulin E-mediated mechanism. | 2004 Oct |
|
Detection of RNA in purified cytomegalovirus virions. | 2004 Sep 1 |
|
Characterization of the AXDH gene and the encoded xylitol dehydrogenase from the dimorphic yeast Arxula adeninivorans. | 2005 Apr |
|
A sensitive assay of red blood cell sorbitol level by high performance liquid chromatography: potential for diagnostic evaluation of diabetes. | 2005 Apr |
|
Microbial production of L-ascorbic acid from D-sorbitol, L-sorbose, L-gulose, and L-sorbosone by Ketogulonicigenium vulgare DSM 4025. | 2005 Mar |
Sample Use Guides
In Vivo Use Guide
Curator's Comment: 3% sorbitol solution is used as irrigation solution during urinary tract surgery
https://dailymed.nlm.nih.gov/dailymed/getFile.cfm?setid=5f7be402-f25a-428e-b81f-6a4a00de894c&type=pdf&name=5f7be402-f25a-428e-b81f-6a4a00de894c
120 mL of a 25 to 30% w/v solution (Laxative)
Route of Administration:
Rectal
In Vitro Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/17200660
Curator's Comment: The effects of allopurinol (10(-6)-10(-5) M), deferoxamine (10(-4) M) and mannitol (10(-4)-5 x 10(-3) M) were tested on the transient contraction induced by nicotine. In conclusion, mannitol (5 x 10(-3) M) significantly reduced contractile response to nicotine on EFS only in high concentration. Whereas in small concentrations mannitol (10(-4) M) statistically did not cause any results. https://www.ncbi.nlm.nih.gov/pubmed/20085573
25 mM sorbitol for 7 days (effect of glucose free medium containing sorbitol on mouse retinal progenitor cells)
Name | Type | Language | ||
---|---|---|---|---|
|
Official Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Brand Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English |
Classification Tree | Code System | Code | ||
---|---|---|---|---|
|
WHO-VATC |
QV04CC01
Created by
admin on Fri Dec 15 15:16:51 GMT 2023 , Edited by admin on Fri Dec 15 15:16:51 GMT 2023
|
||
|
EPA PESTICIDE CODE |
8
Created by
admin on Fri Dec 15 15:16:51 GMT 2023 , Edited by admin on Fri Dec 15 15:16:51 GMT 2023
|
||
|
FDA ORPHAN DRUG |
422914
Created by
admin on Fri Dec 15 15:16:51 GMT 2023 , Edited by admin on Fri Dec 15 15:16:51 GMT 2023
|
||
|
DSLD |
1712 (Number of products:9)
Created by
admin on Fri Dec 15 15:16:51 GMT 2023 , Edited by admin on Fri Dec 15 15:16:51 GMT 2023
|
||
|
NCI_THESAURUS |
C218
Created by
admin on Fri Dec 15 15:16:51 GMT 2023 , Edited by admin on Fri Dec 15 15:16:51 GMT 2023
|
||
|
WHO-ATC |
V04CC01
Created by
admin on Fri Dec 15 15:16:51 GMT 2023 , Edited by admin on Fri Dec 15 15:16:51 GMT 2023
|
||
|
CFR |
21 CFR 184.1835
Created by
admin on Fri Dec 15 15:16:51 GMT 2023 , Edited by admin on Fri Dec 15 15:16:51 GMT 2023
|
||
|
WHO-VATC |
QB05CX02
Created by
admin on Fri Dec 15 15:16:51 GMT 2023 , Edited by admin on Fri Dec 15 15:16:51 GMT 2023
|
||
|
LOINC |
48152-3
Created by
admin on Fri Dec 15 15:16:51 GMT 2023 , Edited by admin on Fri Dec 15 15:16:51 GMT 2023
|
||
|
WHO-ATC |
A06AD18
Created by
admin on Fri Dec 15 15:16:51 GMT 2023 , Edited by admin on Fri Dec 15 15:16:51 GMT 2023
|
||
|
WHO-ATC |
A06AG07
Created by
admin on Fri Dec 15 15:16:51 GMT 2023 , Edited by admin on Fri Dec 15 15:16:51 GMT 2023
|
||
|
CODEX ALIMENTARIUS (GSFA) |
INS-420(I)
Created by
admin on Fri Dec 15 15:16:51 GMT 2023 , Edited by admin on Fri Dec 15 15:16:51 GMT 2023
|
||
|
EU-Orphan Drug |
EU/3/14/1260
Created by
admin on Fri Dec 15 15:16:51 GMT 2023 , Edited by admin on Fri Dec 15 15:16:51 GMT 2023
|
||
|
JECFA EVALUATION |
INS-420(I)
Created by
admin on Fri Dec 15 15:16:51 GMT 2023 , Edited by admin on Fri Dec 15 15:16:51 GMT 2023
|
||
|
WHO-VATC |
QA06AG07
Created by
admin on Fri Dec 15 15:16:51 GMT 2023 , Edited by admin on Fri Dec 15 15:16:51 GMT 2023
|
||
|
WHO-VATC |
QA06AD18
Created by
admin on Fri Dec 15 15:16:51 GMT 2023 , Edited by admin on Fri Dec 15 15:16:51 GMT 2023
|
||
|
WHO-ATC |
B05CX02
Created by
admin on Fri Dec 15 15:16:51 GMT 2023 , Edited by admin on Fri Dec 15 15:16:51 GMT 2023
|
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
506T60A25R
Created by
admin on Fri Dec 15 15:16:51 GMT 2023 , Edited by admin on Fri Dec 15 15:16:51 GMT 2023
|
PRIMARY | |||
|
506T60A25R
Created by
admin on Fri Dec 15 15:16:51 GMT 2023 , Edited by admin on Fri Dec 15 15:16:51 GMT 2023
|
PRIMARY | |||
|
CHEMBL1682
Created by
admin on Fri Dec 15 15:16:51 GMT 2023 , Edited by admin on Fri Dec 15 15:16:51 GMT 2023
|
PRIMARY | |||
|
DTXSID5023588
Created by
admin on Fri Dec 15 15:16:51 GMT 2023 , Edited by admin on Fri Dec 15 15:16:51 GMT 2023
|
PRIMARY | |||
|
D013012
Created by
admin on Fri Dec 15 15:16:51 GMT 2023 , Edited by admin on Fri Dec 15 15:16:51 GMT 2023
|
PRIMARY | |||
|
17924
Created by
admin on Fri Dec 15 15:16:51 GMT 2023 , Edited by admin on Fri Dec 15 15:16:51 GMT 2023
|
PRIMARY | |||
|
SORBITOL
Created by
admin on Fri Dec 15 15:16:51 GMT 2023 , Edited by admin on Fri Dec 15 15:16:51 GMT 2023
|
PRIMARY | |||
|
1617000
Created by
admin on Fri Dec 15 15:16:51 GMT 2023 , Edited by admin on Fri Dec 15 15:16:51 GMT 2023
|
PRIMARY | |||
|
SUB12594MIG
Created by
admin on Fri Dec 15 15:16:51 GMT 2023 , Edited by admin on Fri Dec 15 15:16:51 GMT 2023
|
PRIMARY | |||
|
DB01638
Created by
admin on Fri Dec 15 15:16:51 GMT 2023 , Edited by admin on Fri Dec 15 15:16:51 GMT 2023
|
PRIMARY | |||
|
C29462
Created by
admin on Fri Dec 15 15:16:51 GMT 2023 , Edited by admin on Fri Dec 15 15:16:51 GMT 2023
|
PRIMARY | |||
|
100000092096
Created by
admin on Fri Dec 15 15:16:51 GMT 2023 , Edited by admin on Fri Dec 15 15:16:51 GMT 2023
|
PRIMARY | |||
|
m10121
Created by
admin on Fri Dec 15 15:16:51 GMT 2023 , Edited by admin on Fri Dec 15 15:16:51 GMT 2023
|
PRIMARY | Merck Index | ||
|
SUB20837
Created by
admin on Fri Dec 15 15:16:51 GMT 2023 , Edited by admin on Fri Dec 15 15:16:51 GMT 2023
|
PRIMARY | |||
|
25944
Created by
admin on Fri Dec 15 15:16:51 GMT 2023 , Edited by admin on Fri Dec 15 15:16:51 GMT 2023
|
PRIMARY | |||
|
2462
Created by
admin on Fri Dec 15 15:16:51 GMT 2023 , Edited by admin on Fri Dec 15 15:16:51 GMT 2023
|
PRIMARY | |||
|
5780
Created by
admin on Fri Dec 15 15:16:51 GMT 2023 , Edited by admin on Fri Dec 15 15:16:51 GMT 2023
|
PRIMARY | |||
|
9945
Created by
admin on Fri Dec 15 15:16:51 GMT 2023 , Edited by admin on Fri Dec 15 15:16:51 GMT 2023
|
PRIMARY | RxNorm | ||
|
200-061-5
Created by
admin on Fri Dec 15 15:16:51 GMT 2023 , Edited by admin on Fri Dec 15 15:16:51 GMT 2023
|
PRIMARY | |||
|
50-70-4
Created by
admin on Fri Dec 15 15:16:51 GMT 2023 , Edited by admin on Fri Dec 15 15:16:51 GMT 2023
|
PRIMARY | |||
|
801
Created by
admin on Fri Dec 15 15:16:51 GMT 2023 , Edited by admin on Fri Dec 15 15:16:51 GMT 2023
|
PRIMARY | |||
|
30911
Created by
admin on Fri Dec 15 15:16:51 GMT 2023 , Edited by admin on Fri Dec 15 15:16:51 GMT 2023
|
PRIMARY |
ACTIVE MOIETY